A novel humanized MUC1 antibody–drug conjugate for the treatment of trastuzumab-resistant breast cancer
Tóm tắt
Từ khóa
Tài liệu tham khảo
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2018, 68: 394-424.
Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA, 2006, 295: 2492-2502.
Cauley JA, Lucas FL, Kuller LH, Stone K, Browner W, Cummings SR. Elevated serum estradiol and testosterone concentrations are associated with a high risk for breast cancer. Study of osteoporotic fractures research group. Ann Intern Med, 1999, 130: 270-277.
Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M. American society of clinical oncology/college of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol, 2007, 25: 118-145.
Gajria D, Chandarlapaty S. HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies. Expert Rev Anticancer Ther, 2011, 11: 263-275.
Vu T, Claret FX. Trastuzumab: updated mechanisms of action and resistance in breast cancer. Front Oncol, 2012, 2:
Raina D, Uchida Y, Kharbanda A, Rajabi H, Panchamoorthy G, Jin C, Kharbanda S. Targeting the MUC1-C oncoprotein downregulates HER2 activation and abrogates trastuzumab resistance in breast cancer cells. Oncogene, 2014, 33: 3422-3431.
Lee KM, Nam K, Oh S, Lim J, Kim YP, Lee JW, Yu JH. Extracellular matrix protein 1 regulates cell proliferation and trastuzumab resistance through activation of epidermal growth factor signaling. Breast Cancer Res, 2014, 16:
Farahmand L, Merikhian P, Jalili N, Darvishi B, Majidzadeh AK. Significant role of MUC1 in development of resistance to currently existing anti-cancer therapeutic agents. Curr Cancer Drug Targets, 2018, 18: 737-748.
Lavaud P, Andre F. Strategies to overcome trastuzumab resistance in HER2-overexpressing breast cancers: focus on new data from clinical trials. BMC Med, 2014, 12:
Levitin F, Stern O, Weiss M, Gil-Henn C, Ziv R, Prokocimer Z, Smorodinsky NI. The MUC1 SEA module is a self-cleaving domain. J Biol Chem, 2005, 280: 33374-33386.
Hattrup CL, Gendler SJ. Structure and function of the cell surface (tethered) mucins. Annu Rev Physiol, 2008, 70: 431-457.
Rakha EA, Boyce RW, Abd El-Rehim D, Kurien T, Green AR, Paish EC, Robertson JF. Expression of mucins (MUC1, MUC2, MUC3, MUC4, MUC5AC and MUC6) and their prognostic significance in human breast cancer. Mod Pathol, 2005, 18: 1295-1304.
Nath S, Mukherjee P. MUC1: a multifaceted oncoprotein with a key role in cancer progression. Trends Mol Med, 2014, 20: 332-342.
Kufe DW. MUC1-C oncoprotein as a target in breast cancer: activation of signaling pathways and therapeutic approaches. Oncogene, 2013, 32: 1073-1081.
Pandey P, Kharbanda S, Kufe D. Association of the DF3/MUC1 breast cancer antigen with Grb2 and the Sos/Ras exchange protein. Cancer Res, 1995, 55: 4000-4003.
Pochampalli MR, Bitler BG, Schroeder JA. Transforming growth factor alpha dependent cancer progression is modulated by Muc1. Cancer Res, 2007, 67: 6591-6598.
Li G, Zhao L, Li W, Fan K, Qian W, Hou S, Wang H. Feedback activation of STAT3 mediates trastuzumab resistance via upregulation of MUC1 and MUC4 expression. Oncotarget, 2014, 5: 8317-8329.
Syrkina MS, Rubtsov MA. MUC1 in cancer immunotherapy - new hope or phantom menace?. Biochemistry (Mosc), 2019, 84: 773-781.
Pichinuk E, Chalik M, Benhar I, Ginat-Koton R, Ziv R, Smorodinsky NI, Haran G. In vivo anti-MUC1(+) tumor activity and sequences of high-affinity anti-MUC1-SEA antibodies. Cancer Immunol Immunother, 2020, 69: 1337-1352.
Kufe DW. Targeting the human MUC1 oncoprotein: a tale of two proteins. Cancer Biol Ther, 2008, 7: 81-84.
Wu G, Maharjan S, Kim D, Kim JN, Park BK, Koh H, Moon K. A novel monoclonal antibody targets Mucin1 and attenuates growth in pancreatic cancer model. Int J Mol Sci, 2018, 19:
Wu G, Kim D, Kim JN, Park S, Maharjan S, Koh H, Moon K. A Mucin1 C-terminal subunit-directed monoclonal antibody targets overexpressed Mucin1 in breast cancer. Theranostics, 2018, 8: 78-91.
Wang Z, Raifu M, Howard M, Smith L, Hansen D, Goldsby R, Ratner D. Universal PCR amplification of mouse immunoglobulin gene variable regions: the design of degenerate primers and an assessment of the effect of DNA polymerase 3’ to 5’ exonuclease activity. J Immunol Methods, 2000, 233: 167-177.
Ye J, Ma N, Madden TL, Ostell JM. IgBLAST: an immunoglobulin variable domain sequence analysis tool. Nucleic Acids Res, 2013, 41: W34-W40.
Kabat EA, Wu TT. Identical V region amino acid sequences and segments of sequences in antibodies of different specificities. Relative contributions of VH and VL genes, minigenes, and complementarity-determining regions to binding of antibody-combining sites. J Immunol, 1991, 147: 1709-1719.
Ling WL, Lua WH, Poh JJ, Yeo JY, Lane DP, Gan SK. Effect of VH-VL families in pertuzumab and trastuzumab recombinant production, Her2 and FcgammaIIA binding. Front Immunol, 2018, 9:
Li P, Yang L, Li T, Bin S, Sun B, Huang Y, Yang K. The third generation Anti-HER2 chimeric antigen receptor mouse T cells alone or together with Anti-PD1 antibody inhibits the growth of mouse breast tumor cells expressing HER2 in vitro and in immune competent mice. Front Oncol, 2020, 10:
Deng M, Gui X, Kim J, Xie L, Chen W, Li Z, He L. LILRB4 signalling in leukaemia cells mediates T cell suppression and tumour infiltration. Nature, 2018, 562: 605-609.
Yao X, Jiang J, Wang X, Huang C, Li D, Xie K, Xu Q. A novel humanized anti-HER2 antibody conjugated with MMAE exerts potent anti-tumor activity. Breast Cancer Res Treat, 2015, 153: 123-133.
Li H, Yuan W, Bin S, Wu G, Li P, Liu M, Yang J. Overcome trastuzumab resistance of breast cancer using anti-HER2 chimeric antigen receptor T cells and PD1 blockade. Am J Cancer Res, 2020, 10: 688-703.
Birrer MJ, Moore KN, Betella I, Bates RC. Antibody-drug conjugate-based therapeutics: state of the science. J Natl Cancer Inst, 2019, 111: 538-549.
Maderna A, Leverett CA. Recent advances in the development of new auristatins: structural modifications and application in antibody drug conjugates. Mol Pharm, 2015, 12: 1798-1812.
Zhou R, Yazdanifar M, Roy LD, Whilding LM, Gavrill A, Maher J, Mukherjee P. CAR T cells targeting the tumor MUC1 glycoprotein reduce triple-negative breast cancer growth. Front Immunol, 2019, 10:
You F, Jiang L, Zhang B, Lu Q, Zhou Q, Liao X, Wu H. Phase 1 clinical trial demonstrated that MUC1 positive metastatic seminal vesicle cancer can be effectively eradicated by modified Anti-MUC1 chimeric antigen receptor transduced T cells. Sci China Life Sci, 2016, 59: 386-397.
Wilkie S, Picco G, Foster J, Davies DM, Julien S, Cooper L, Arif S. Retargeting of human T cells to tumor-associated MUC1: the evolution of a chimeric antigen receptor. J Immunol, 2008, 180: 4901-4909.
Posey AD, Schwab RD, Boesteanu AC, Steentoft C, Mandel U, Engels B, Stone JD. Engineered CAR T cells targeting the cancer-associated Tn-glycoform of the membrane Mucin MUC1 control adenocarcinoma. Immunity, 2016, 44: 1444-1454.
Zhou D, Xu L, Huang W, Tonn T. Epitopes of MUC1 tandem repeats in cancer as revealed by antibody crystallography: toward glycopeptide signature-guided therapy. Molecules, 2018, 23:
Price MR, Rye PD, Petrakou E, Murray A, Brady K, Imai S, Haga S. Summary report on the ISOBM TD-4 Workshop: analysis of 56 monoclonal antibodies against the MUC1 mucin. San Diego, Calif., November 17- 23,1996. Tumour Biol, 1998, 19: 1-20.
Song EY, Qu CF, Rizvi SM, Raja C, Beretov J, Morgenstern A, Apostolidis C. Bismuth-213 radioimmunotherapy with C595 anti-MUC1 monoclonal antibody in an ovarian cancer ascites model. Cancer Biol Ther, 2008, 7: 76-80.
Wang L, Chen H, Pourgholami MH, Beretov J, Hao J, Chao H, Perkins AC. Anti-MUC1 monoclonal antibody (C595) and docetaxel markedly reduce tumor burden and ascites, and prolong survival in an in vivo ovarian cancer model. PLoS One, 2011, 6:
Ibrahim NK, Yariz KO, Bondarenko I, Manikhas A, Semiglazov V, Alyasova A, Komisarenko V. Randomized phase II trial of letrozole plus anti-MUC1 antibody AS1402 in hormone receptor-positive locally advanced or metastatic breast cancer. Clin Cancer Res, 2011, 17: 6822-6830.
Oei AL, Verheijen RH, Seiden MV, Benigno BB, Lopes A, Soper JT, Epenetos AA. Decreased intraperitoneal disease recurrence in epithelial ovarian cancer patients receiving intraperitoneal consolidation treatment with yttrium-90-labeled murine HMFG1 without improvement in overall survival. Int J Cancer, 2007, 120: 2710-2714.
de Bono JS, Rha SY, Stephenson J, Schultes BC, Monroe P, Eckhardt GS, Hammond LA. Phase I trial of a murine antibody to MUC1 in patients with metastatic cancer: evidence for the activation of humoral and cellular antitumor immunity. Ann Oncol, 2004, 15: 1825-1833.
Pichinuk E, Benhar I, Jacobi O, Chalik M, Weiss L, Ziv R, Sympson C. Antibody targeting of cell-bound MUC1 SEA domain kills tumor cells. Cancer Res, 2012, 72: 3324-3336.
Panchamoorthy G, Jin C, Raina D, Bharti A, Yamamoto M, Adeebge D, Zhao Q. Targeting the human MUC1-C oncoprotein with an antibody-drug conjugate. JCI Insight, 2018, 3:
Nahta R. Pharmacological strategies to overcome HER2 cross-talk and Trastuzumab resistance. Curr Med Chem, 2012, 19: 1065-1075.
Swain SM, Kim SB, Cortes J, Ro J, Semiglazov V, Campone M, Ciruelos E. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol, 2013, 14: 461-471.
Dieras V, Bachelot T. The success story of trastuzumab emtansine, a targeted therapy in HER2-positive breast cancer. Target Oncol, 2014, 9: 111-122.
Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, Pegram M. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med, 2012, 367: 1783-1791.
Khongorzul P, Ling CJ, Khan FU, Ihsan AU, Zhang J. Antibody-drug conjugates: a comprehensive review. Mol Cancer Res, 2020, 18: 3-19.
Berger GK, McBride A, Lawson S, Royball K, Yun S, Gee K, Bin Riaz I. Brentuximab vedotin for treatment of non-Hodgkin lymphomas: a systematic review. Crit Rev Oncol Hematol, 2017, 109: 42-50.